145 related articles for article (PubMed ID: 37097550)
1. Cost-effectiveness of general practitioner- versus surgeon-led colon cancer survivorship care: an economic evaluation alongside a randomised controlled trial.
Vos JAM; El Alili M; Duineveld LAM; Wieldraaijer T; Wind J; Sert E; Donkervoort SC; Govaert MJPM; van Geloven NAW; van de Ven AWH; Heuff G; van Weert HCPM; Bosmans JE; van Asselt KM;
J Cancer Surviv; 2023 Apr; ():. PubMed ID: 37097550
[TBL] [Abstract][Full Text] [Related]
2. Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial.
Vos JAM; Duineveld LAM; Wieldraaijer T; Wind J; Busschers WB; Sert E; Tanis PJ; Verdonck-de Leeuw IM; van Weert HCPM; van Asselt KM;
Lancet Oncol; 2021 Aug; 22(8):1175-1187. PubMed ID: 34224671
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial.
Augestad KM; Norum J; Dehof S; Aspevik R; Ringberg U; Nestvold T; Vonen B; Skrøvseth SO; Lindsetmo RO
BMJ Open; 2013; 3(4):. PubMed ID: 23564936
[TBL] [Abstract][Full Text] [Related]
4. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
6. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of custom-made insoles versus usual care in patients with plantar heel pain in primary care: cost-effectiveness analysis of a randomised controlled trial.
Rasenberg N; van Middelkoop M; Bierma-Zeinstra SMA; El Alili M; Bindels P; Bosmans J
BMJ Open; 2021 Nov; 11(11):e051866. PubMed ID: 34732484
[TBL] [Abstract][Full Text] [Related]
8. SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer.
Jefford M; Emery JD; James Martin A; De Abreu Lourenco R; Lisy K; Grunfeld E; Mohamed MA; King D; Tebbutt NC; Lee M; Mehrnejad A; Burgess A; Marker J; Eggins R; Carrello J; Thomas H; Schofield P
EClinicalMedicine; 2023 Dec; 66():102346. PubMed ID: 38094163
[TBL] [Abstract][Full Text] [Related]
9. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT.
Serfaty M; King M; Nazareth I; Moorey S; Aspden T; Tookman A; Mannix K; Gola A; Davis S; Wood J; Jones L
Health Technol Assess; 2019 May; 23(19):1-106. PubMed ID: 31097078
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of systematic fast-track transition from oncological treatment to specialised palliative care at home for patients and their caregivers: the DOMUS trial.
Halling CMB; Wolf RT; Sjøgren P; Von Der Maase H; Timm H; Johansen C; Kjellberg J
BMC Palliat Care; 2020 Sep; 19(1):142. PubMed ID: 32933489
[TBL] [Abstract][Full Text] [Related]
11. Follow-up strategies following completion of primary cancer treatment in adult cancer survivors.
Høeg BL; Bidstrup PE; Karlsen RV; Friberg AS; Albieri V; Dalton SO; Saltbæk L; Andersen KK; Horsboel TA; Johansen C
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31750936
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trial.
van der Hout A; Jansen F; van Uden-Kraan CF; Coupé VM; Holtmaat K; Nieuwenhuijzen GA; Hardillo JA; de Jong RJB; Tiren-Verbeet NL; Sommeijer DW; de Heer K; Schaar CG; Sedee RJE; Bosscha K; van den Brekel MWM; Petersen JF; Westerman M; Honings J; Takes RP; Houtenbos I; van den Broek WT; de Bree R; Jansen P; Eerenstein SEJ; Leemans CR; Zijlstra JM; Cuijpers P; van de Poll-Franse LV; Verdonck-de Leeuw IM
J Cancer Surviv; 2021 Feb; 15(1):77-86. PubMed ID: 32656739
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of a Decision Support Tool to guide intensity of mental health care in general practice: the Link-me pragmatic randomised controlled trial.
Chatterton ML; Harris M; Burgess P; Fletcher S; Spittal MJ; Faller J; Palmer VJ; Chondros P; Bassilios B; Pirkis J; Gunn J; Mihalopoulos C
BMC Prim Care; 2022 Sep; 23(1):236. PubMed ID: 36109694
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of internet-mediated cognitive behavioural therapy for depression in the primary care setting: results based on a controlled trial.
Holst A; Björkelund C; Metsini A; Madsen JH; Hange D; Petersson EL; Eriksson MC; Kivi M; Andersson PÅ; Svensson M
BMJ Open; 2018 Jun; 8(6):e019716. PubMed ID: 29903785
[TBL] [Abstract][Full Text] [Related]
15. Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion.
Heslin M; Patel A; Stahl D; Gardner-Sood P; Mushore M; Smith S; Greenwood K; Onagbesan O; O'Brien C; Fung C; Ohlsen R; Hopkins D; Lowe P; Arbuthnot M; Mutatsa S; Todd G; Kolliakou A; Lally J; Stubbs B; Ismail K; David A; Murray R; Atakan Z; Gaughran F
BMC Psychiatry; 2017 Dec; 17(1):407. PubMed ID: 29273021
[TBL] [Abstract][Full Text] [Related]
16. Action Seniors! Cost-Effectiveness Analysis of a Secondary Falls Prevention Strategy Among Community-Dwelling Older Fallers.
Davis JC; Khan KM; Hsu CL; Chan P; Cook WL; Dian L; Liu-Ambrose T
J Am Geriatr Soc; 2020 Sep; 68(9):1988-1997. PubMed ID: 32472567
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, Cost-effectiveness, and Cost-Utility of a Digital Alcohol Moderation Intervention for Cancer Survivors: Health Economic Evaluation and Outcomes of a Pragmatic Randomized Controlled Trial.
Mujcic A; Blankers M; Boon B; Berman AH; Riper H; van Laar M; Engels R
J Med Internet Res; 2022 Feb; 24(2):e30095. PubMed ID: 35103605
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Concise Cognitive Behavioural Therapy and/or Pharmacotherapy for Depressive and Anxiety Disorders.
Meuldijk D; Carlier IV; van Vliet IM; van Hemert AM; Zitman FG; van den Akker-van Marle ME
J Ment Health Policy Econ; 2015 Dec; 18(4):175-83. PubMed ID: 26729009
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care.
Eveleigh R; Grutters J; Muskens E; Oude Voshaar R; van Weel C; Speckens A; Lucassen P
Fam Pract; 2014 Oct; 31(5):578-84. PubMed ID: 25121977
[TBL] [Abstract][Full Text] [Related]
20. Patient experiences of GP-led colon cancer survivorship care: a Dutch mixed-methods evaluation.
Vos JA; van Miltenburg VE; Beverdam FH; van Weert HC; van Asselt KM;
Br J Gen Pract; 2023 Feb; 73(727):e115-e123. PubMed ID: 36316164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
